Bacs-Kiskun Megyei Korhaz Trials

Bacs-Kiskun Megyei Korhaz	Welcome, Profile Billing Logout

54 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhang, Jie

NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting

8250

RoW

Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy

Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.

Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases

04/25

NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

Recruiting

424

RoW

Victoza®., Metformin Hydrochloride, TQZ2451

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Type 2 Diabetes

12/21

NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection

Recruiting

RoW

Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Mental Health Issue

03/26

MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

	Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
	Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
	Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
	Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
	Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD

Completed

806

Europe, Canada, US, RoW

Placebo, Mepolizumab

GlaxoSmithKline, PPD DEVELOPMENT, LP

Pulmonary Disease, Chronic Obstructive

08/24

NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting

2100

Europe, Canada, Japan, US, RoW

Rimegepant/BHV3000, Matching placebo

Pfizer

Pediatric Migraine

01/29

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed

250

RoW

GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table

Sunshine Lake Pharma Co., Ltd.

Chronic HBV Infection

06/22

09/23

NCT06009861: Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Recruiting

110

RoW

Tislelizumab, Albumin-Bound Paclitaxel, Cisplatin

Peking University Hospital of Stomatology

Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma

06/24

08/27

NCT06106685: Washed Microbiota Transplantation for Chronic Constipation in Adults

Recruiting

1/2

RoW

High-dose washed microbiota suspension, WMT-001, Low-dose washed microbiota suspension, Placebo

The Second Hospital of Nanjing Medical University

Constipation

07/26

12/26

NCT06002425: Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

Recruiting

N/A

400

Europe, US, RoW

Clinician-Directed Treatment Plan, ChatGPT-Assisted Treatment Plan

Chinese Academy of Sciences, ZhuHai Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Jiangmen Central Hospital, Peking University Cancer Hospital (Inner Mongolia Campus), San Raffaele University Hospital, Italy, University Hospital Magdeburg, Germany, City of Hope Medical Center

Gastrointestinal Neoplasm Malignant

09/23

12/28

NCT06141512: Improvements in Aerobic Fitness With Exercise Training: the Role of Myokines

Active, not recruiting

N/A

Europe

Reduced-exertion high-intensity interval training (REHIT), Sprint interval training (SIT)

University of Stirling

General Health

06/24

06/25

NCT03641391: Awake Intraoperative Language Mapping and Chinese Probabilistic Map Construction

Not yet recruiting

N/A

300

RoW

Intraoperative direct cortical electrical stimulation, Intraoperative direct subcortical electrical stimulation

Huashan Hospital, Shanghai Zhongshan Hospital, Huashan Hospital North, Fudan University

Glioma

12/23

NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Recruiting

N/A

16000

RoW

phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2

Wuhan Union Hospital, China, Peking University First Hospital

Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease

12/23

12/24

NCT03808779: A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.

Recruiting

N/A

200

RoW

Radiofrequency Ablation, RFA, Conventional Surgery, Total thyroidectomy/Thyroid lobectomy

Second Affiliated Hospital, School of Medicine, Zhejiang University

Papillary Thyroid Microcarcinoma

02/24

TRIPHY, NCT06480890: Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients

Recruiting

N/A

359

RoW

Chiesi Farmaceutici S.p.A.

Chronic Obstructive Pulmonary Disease

10/25

TEAS/ASD, NCT06763237: Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder

Not yet recruiting

N/A

RoW

abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS), TEAS, Applied Behavior Analysis (ABA) therapy

First Affiliated Hospital Xi'an Jiaotong University, Xian Children's Hospital

Autism Spectrum Disorder, Autism in Children

01/26

NCT06106698: Washed Microbiota Transplantation for Clostridioides Difficile Infection

Recruiting

N/A

100

RoW

WMT

The Second Hospital of Nanjing Medical University

Clostridioides Difficile Infection

07/29

12/29

Horvath, Zsolt

NCT05874401: Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Recruiting

302

Europe, RoW

Trilaciclib, G1T28, CDK 4/6 inhibitor, cyclin-dependent kinase 4/6 inhibitor, Placebo, Topotecan, Hycamtin

G1 Therapeutics, Inc.

Extensive-stage Small-cell Lung Cancer

07/27

postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting

368

Europe, US, RoW

Abemaciclib, Fulvestrant, Placebo

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasm, Neoplasm Metastasis

02/24

02/26

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms

09/25

08/27

CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

02/24

10/27

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

102

Europe, Canada, US, RoW

DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan

ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma

10/24

04/25

THIO-101, NCT05208944 / 2021-005136-34: THIO Sequenced with Cemiplimab in Advanced NSCLC

Nov 2024 - Nov 2024 : Safety and efficacy data for NSCLC

Active, not recruiting

227

Europe, RoW

6-Thio-2'-Deoxyguanosine, 6-thio-dG, THIO, Cemiplimab, LIBTAYO®

Maia Biotechnology, MAIA Biotechnology, Inc.

Carcinoma, Non-Small-Cell Lung

12/25

10/26

Shi, Yanxia

PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Recruiting

320

RoW

NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel

Shi Yanxia

Breast Cancer Model, Effects of Chemotherapy, Breast Cancer

03/18

03/23

NCT05244577: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

Recruiting

RoW

Olanzapine Tablets, Olanzapine, Placebo

Shi Yanxia

Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin

12/23

03/24

B2023-686-01, NCT06268652: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Recruiting

302

RoW

Organoid-guided personalized treatment, OGPT, Gemcitabine, Gemzar, Capecitabine, Xeloda, Vinorelbine, Navelbine, Eribulin, Halaven

Sun Yat-sen University

Breast Cancer, Refractory Breast Carcinoma

02/26

01/28

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

314

RoW

Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Breast Cancer

07/25

01/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

NCT06768931: Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

Recruiting

192

RoW

Biolosion (oral probiotic compound preparation)

Sun Yat-sen University

Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy, Probiotic

01/30

02/35

IMPROVE, NCT06904573: Probiotics in Advanced Urothelial Carcinoma

Recruiting

222

RoW

Probiotics Compound (Biolosion), Nab-paclitaxel, Cisplatin, Gemcitabine, Disitamab vedotin, Enfortumab Vedotin, Pembrolizumab, Toripalimab

Sun Yat-sen University

Advanced Urothelial Carcinoma, Probiotics, Immunotherapy

01/27

01/28

NCT05760053: Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma

Recruiting

RoW

EP/EC+PD-1, Etoposide, Cisplatin or Carboplatin, plus Toripalimab

Sun Yat-sen University

Toripalimab, First-line Treatment

02/25

02/26

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer

08/25

07/26

NCT06639347: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Recruiting

1/2

RoW

SHR-A2102, Adebrelimab injection, SHR-8068 injection

Shanghai Hengrui Pharmaceutical Co., Ltd.

Advanced Urothelial Carcinoma

05/27

NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting

150

RoW

SPH5030 tablets

Shanghai Pharmaceuticals Holding Co., Ltd

HER2-positive Advanced Solid Tumors

12/25

BOCIS, NCT06900647: Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Recruiting

RoW

Bortezomib (B), Cisplatin (CDDP)

Sun Yat-sen University

Metastatic Breast Cancer, Recurrent Breast Cancer

06/26

06/28

Song, Qibin

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Jan 2022 - Jun 2022 : Interim data from CAPSTONE trial for NSCLC

Recruiting

RoW

Camrelizumab, SHR-1210, Famitinib, SHR-1020

Qian Chu, Jiangsu HengRui Medicine Co., Ltd.

Sarcomatoid Carcinoma of Lung

12/24

06/25

ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Not yet recruiting

Almonertinib, HS-10296

Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.

Lung Cancer, EGFR Gene Mutation

01/24

NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Recruiting

1/2

160

RoW

YK-029A

Suzhou Puhe Pharmaceutical Technology Co., LTD

Treatment, Treatment Side Effects

12/23

05/24

NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors

Recruiting

RoW

BL-M02D1

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Breast Cancer

12/24

NCT05868915: HV-101 for Patients With Advanced Solid Tumors

Recruiting

RoW

HV-101

Hervor Therapeutics, Renmin Hospital of Wuhan University

Advanced Solid Tumors

05/25

03/26

Zhang, Anqin

TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Recruiting

970

RoW

Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin

Shanghai Jiao Tong University School of Medicine

Breast Neoplasm

12/22

12/23

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT02062489: Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

Recruiting

688

RoW

Tamoxifen, Nolvadex, Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Cancer

05/25

05/26

LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting

350

RoW

GB491 combined with Letrozole, Placebo combined with Letrozole

Genor Biopharma Co., Ltd.

Breast Cancer

01/26

01/27

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT04975451: ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Not yet recruiting

RoW

Anlotinib

Anqin Zhang

Breast Cancer

05/24

Nagy, Andras

KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Completed

233

Europe, Japan, US, RoW

LY3473329, Placebo

Eli Lilly and Company

Lipoprotein Disorder

03/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhang, Jie

NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting

8250

RoW

Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy

Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.

04/25

NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

Recruiting

424

RoW

Victoza®., Metformin Hydrochloride, TQZ2451

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Type 2 Diabetes

12/21

NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection

Recruiting

RoW

Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Mental Health Issue

03/26

MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

	Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
	Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
	Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
	Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
	Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD

Completed

806

Europe, Canada, US, RoW

Placebo, Mepolizumab

GlaxoSmithKline, PPD DEVELOPMENT, LP

Pulmonary Disease, Chronic Obstructive

08/24

NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting

2100

Europe, Canada, Japan, US, RoW

Rimegepant/BHV3000, Matching placebo

Pfizer

Pediatric Migraine

01/29

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed

250

RoW

GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table

Sunshine Lake Pharma Co., Ltd.

Chronic HBV Infection

06/22

09/23

NCT06009861: Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Recruiting

110

RoW

Tislelizumab, Albumin-Bound Paclitaxel, Cisplatin

Peking University Hospital of Stomatology

Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma

06/24

08/27

NCT06106685: Washed Microbiota Transplantation for Chronic Constipation in Adults

Recruiting

1/2

RoW

High-dose washed microbiota suspension, WMT-001, Low-dose washed microbiota suspension, Placebo

The Second Hospital of Nanjing Medical University

Constipation

07/26

12/26

NCT06002425: Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models

Recruiting

N/A

400

Europe, US, RoW

Clinician-Directed Treatment Plan, ChatGPT-Assisted Treatment Plan

Gastrointestinal Neoplasm Malignant

09/23

12/28

NCT06141512: Improvements in Aerobic Fitness With Exercise Training: the Role of Myokines

Active, not recruiting

N/A

Europe

Reduced-exertion high-intensity interval training (REHIT), Sprint interval training (SIT)

University of Stirling

General Health

06/24

06/25

NCT03641391: Awake Intraoperative Language Mapping and Chinese Probabilistic Map Construction

Not yet recruiting

N/A

300

RoW

Intraoperative direct cortical electrical stimulation, Intraoperative direct subcortical electrical stimulation

Huashan Hospital, Shanghai Zhongshan Hospital, Huashan Hospital North, Fudan University

Glioma

12/23

NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Recruiting

N/A

16000

RoW

Wuhan Union Hospital, China, Peking University First Hospital

Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease

12/23

12/24

NCT03808779: A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.

Recruiting

N/A

200

RoW

Radiofrequency Ablation, RFA, Conventional Surgery, Total thyroidectomy/Thyroid lobectomy

Second Affiliated Hospital, School of Medicine, Zhejiang University

Papillary Thyroid Microcarcinoma

02/24

TRIPHY, NCT06480890: Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients

Recruiting

N/A

359

RoW

Chiesi Farmaceutici S.p.A.

Chronic Obstructive Pulmonary Disease

10/25

TEAS/ASD, NCT06763237: Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder

Not yet recruiting

N/A

RoW

abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS), TEAS, Applied Behavior Analysis (ABA) therapy

First Affiliated Hospital Xi'an Jiaotong University, Xian Children's Hospital

Autism Spectrum Disorder, Autism in Children

01/26

NCT06106698: Washed Microbiota Transplantation for Clostridioides Difficile Infection

Recruiting

N/A

100

RoW

WMT

The Second Hospital of Nanjing Medical University

Clostridioides Difficile Infection

07/29

12/29

Horvath, Zsolt

NCT05874401: Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Recruiting

302

Europe, RoW

Trilaciclib, G1T28, CDK 4/6 inhibitor, cyclin-dependent kinase 4/6 inhibitor, Placebo, Topotecan, Hycamtin

G1 Therapeutics, Inc.

Extensive-stage Small-cell Lung Cancer

07/27

postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting

368

Europe, US, RoW

Abemaciclib, Fulvestrant, Placebo

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasm, Neoplasm Metastasis

02/24

02/26

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

09/25

08/27

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

02/24

10/27

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

102

Europe, Canada, US, RoW

DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan

ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma

10/24

04/25

THIO-101, NCT05208944 / 2021-005136-34: THIO Sequenced with Cemiplimab in Advanced NSCLC

Nov 2024 - Nov 2024 : Safety and efficacy data for NSCLC

Active, not recruiting

227

Europe, RoW

6-Thio-2'-Deoxyguanosine, 6-thio-dG, THIO, Cemiplimab, LIBTAYO®

Maia Biotechnology, MAIA Biotechnology, Inc.

Carcinoma, Non-Small-Cell Lung

12/25

10/26

Shi, Yanxia

PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Recruiting

320

RoW

NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel

Shi Yanxia

Breast Cancer Model, Effects of Chemotherapy, Breast Cancer

03/18

03/23

NCT05244577: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

Recruiting

RoW

Olanzapine Tablets, Olanzapine, Placebo

Shi Yanxia

Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin

12/23

03/24

B2023-686-01, NCT06268652: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Recruiting

302

RoW

Organoid-guided personalized treatment, OGPT, Gemcitabine, Gemzar, Capecitabine, Xeloda, Vinorelbine, Navelbine, Eribulin, Halaven

Sun Yat-sen University

Breast Cancer, Refractory Breast Carcinoma

02/26

01/28

EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting

866

Europe, Japan, US, RoW

Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219

Eli Lilly and Company, Eli Lilly and Company

Breast Neoplasms, Neoplasm Metastasis

06/24

08/27

FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

314

RoW

Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Breast Cancer

07/25

01/26

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

NCT06768931: Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

Recruiting

192

RoW

Biolosion (oral probiotic compound preparation)

Sun Yat-sen University

Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy, Probiotic

01/30

02/35

IMPROVE, NCT06904573: Probiotics in Advanced Urothelial Carcinoma

Recruiting

222

RoW

Probiotics Compound (Biolosion), Nab-paclitaxel, Cisplatin, Gemcitabine, Disitamab vedotin, Enfortumab Vedotin, Pembrolizumab, Toripalimab

Sun Yat-sen University

Advanced Urothelial Carcinoma, Probiotics, Immunotherapy

01/27

01/28

NCT05760053: Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma

Recruiting

RoW

EP/EC+PD-1, Etoposide, Cisplatin or Carboplatin, plus Toripalimab

Sun Yat-sen University

Toripalimab, First-line Treatment

02/25

02/26

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

08/25

07/26

NCT06639347: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Recruiting

1/2

RoW

SHR-A2102, Adebrelimab injection, SHR-8068 injection

Shanghai Hengrui Pharmaceutical Co., Ltd.

Advanced Urothelial Carcinoma

05/27

NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting

150

RoW

SPH5030 tablets

Shanghai Pharmaceuticals Holding Co., Ltd

HER2-positive Advanced Solid Tumors

12/25

BOCIS, NCT06900647: Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Recruiting

RoW

Bortezomib (B), Cisplatin (CDDP)

Sun Yat-sen University

Metastatic Breast Cancer, Recurrent Breast Cancer

06/26

06/28

Song, Qibin

SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting

1016

Europe, Canada, Japan, US, RoW

LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed

Eli Lilly and Company, Loxo Oncology, Inc.

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

10/26

10/29

CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Jan 2022 - Jun 2022 : Interim data from CAPSTONE trial for NSCLC

Recruiting

RoW

Camrelizumab, SHR-1210, Famitinib, SHR-1020

Qian Chu, Jiangsu HengRui Medicine Co., Ltd.

Sarcomatoid Carcinoma of Lung

12/24

06/25

ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Not yet recruiting

Almonertinib, HS-10296

Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.

Lung Cancer, EGFR Gene Mutation

01/24

NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Recruiting

1/2

160

RoW

YK-029A

Suzhou Puhe Pharmaceutical Technology Co., LTD

Treatment, Treatment Side Effects

12/23

05/24

NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors

Recruiting

RoW

BL-M02D1

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Breast Cancer

12/24

NCT05868915: HV-101 for Patients With Advanced Solid Tumors

Recruiting

RoW

HV-101

Hervor Therapeutics, Renmin Hospital of Wuhan University

Advanced Solid Tumors

05/25

03/26

Zhang, Anqin

TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Recruiting

970

RoW

Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin

Shanghai Jiao Tong University School of Medicine

Breast Neoplasm

12/22

12/23

TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting

531

RoW

JS001, Nab-Paclitaxel, Placebo

Shanghai Junshi Bioscience Co., Ltd.

Triple-Negative Breast Cancer

12/24

12/25

NCT02062489: Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

Recruiting

688

RoW

Tamoxifen, Nolvadex, Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Cancer

05/25

05/26

LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting

350

RoW

GB491 combined with Letrozole, Placebo combined with Letrozole

Genor Biopharma Co., Ltd.

Breast Cancer

01/26

01/27

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

8000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

NCT04975451: ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Not yet recruiting

RoW

Anlotinib

Anqin Zhang

Breast Cancer

05/24

Nagy, Andras

KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Completed

233

Europe, Japan, US, RoW

LY3473329, Placebo

Eli Lilly and Company

Lipoprotein Disorder

03/24

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites